Lung cancer is the main cause of cancer-related mortality worldwide. Patients with early stage (I-II) non-small cell lung cancer (NSCLC), have a much better prognosis than those diagnosed at late stage. Thus, the development of sensitive and non-invasive methods for screening individuals at high risk for NSCLC is needed. microRNAs (miRNAs) have been suggested as a novel class of tumor biomarkers; their stability in biofluids and their change in levels in disease suggest their potential application as circulating biomarkers. Upon a critical review of the literature, we selected 8 miRNAs for a two-step screening for early lung cancer, based on their reported sensitivity and specificity and the fact that are not influenced by hemolysisa. Since smoking habit or inflammatory conditions may influence miRNA levels in serum, we quantified miRNAs of our panels in three groups of controls (non-smokers, smokers and COPD patients) and in stage I-II NSCLC patients. Droplet digital PCR was applied for quantification of miRNAs. The two-step screening is composed of a panel of 4 miRNAs endowed with high sensitivity and a second panel at high specificity. The scan. For 3 of the 6 miRNAs analyzed there was no significant difference among control subgroups (non-smokers, smokers, and subject with Chronic Obstructive Pulmonary Disease), whereas miRNA levels were expressed at significantly different levels in tumor and control groups, confirming their possible role as biomarkers previously proposed in the literature. The selected miRNAs may help to identify high risk subjects who need further investigation for the presence of early NSCLC; in particular, miR-223 showed a good accuracy in distinguishing tumor samples from controls. REFERENCES 1. Moretti F, D’Antona P, Finardi E, Barbetta M, Dominioni L, Poli A, Gini E, Noonan DM, Imperatori A, Rotolo N, Cattoni M, Campomenosi P. Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer Oncotarget. 2017.
Serum miRNAs as biomarkers for early diagnosis of non small cell lung cancer
Paola D’Antona;Elena Lombardi;Elisabetta Gini;Sarah Grossi;Lorenzo Dominioni;Douglas M. Noonan;Paola Campomenosi
2017-01-01
Abstract
Lung cancer is the main cause of cancer-related mortality worldwide. Patients with early stage (I-II) non-small cell lung cancer (NSCLC), have a much better prognosis than those diagnosed at late stage. Thus, the development of sensitive and non-invasive methods for screening individuals at high risk for NSCLC is needed. microRNAs (miRNAs) have been suggested as a novel class of tumor biomarkers; their stability in biofluids and their change in levels in disease suggest their potential application as circulating biomarkers. Upon a critical review of the literature, we selected 8 miRNAs for a two-step screening for early lung cancer, based on their reported sensitivity and specificity and the fact that are not influenced by hemolysisa. Since smoking habit or inflammatory conditions may influence miRNA levels in serum, we quantified miRNAs of our panels in three groups of controls (non-smokers, smokers and COPD patients) and in stage I-II NSCLC patients. Droplet digital PCR was applied for quantification of miRNAs. The two-step screening is composed of a panel of 4 miRNAs endowed with high sensitivity and a second panel at high specificity. The scan. For 3 of the 6 miRNAs analyzed there was no significant difference among control subgroups (non-smokers, smokers, and subject with Chronic Obstructive Pulmonary Disease), whereas miRNA levels were expressed at significantly different levels in tumor and control groups, confirming their possible role as biomarkers previously proposed in the literature. The selected miRNAs may help to identify high risk subjects who need further investigation for the presence of early NSCLC; in particular, miR-223 showed a good accuracy in distinguishing tumor samples from controls. REFERENCES 1. Moretti F, D’Antona P, Finardi E, Barbetta M, Dominioni L, Poli A, Gini E, Noonan DM, Imperatori A, Rotolo N, Cattoni M, Campomenosi P. Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer Oncotarget. 2017.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
